A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 72, Issue 6, 2012, Pages 479-483

  Başar, Ömer ^a   Akbal, Erdem ^b   Köklü, Seyfettin ^b   Koçak, Erdem ^b   Tuna, Yaşar ^c   Ekiz, Fuat ^a   Gültuna, Selcan ^d   Ylmaz, Fatma Meriç ^b   Aydogan, Temuçin ^e  

^a Department of Gastroenterology   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

^e HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Appetite; Liver enzymes; Nesfatin 1; Non alcoholic fatty liver disease; Obesity

Indexed keywords

GLUCOSE; HORMONE; LIVER ENZYME; NESFATIN 1; UNCLASSIFIED DRUG;

ADULT; APPETITE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULTRASOUND;

ADULT; APPETITE; CALCIUM-BINDING PROTEINS; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FATTY LIVER; FEMALE; HUMANS; MALE; NERVE TISSUE PROTEINS; PEPTIDES;

EID: 84866395891     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2012.699097     Document Type: Article

References (27)

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332:1519-23.
2. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60:313-26.
3. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J, Serfaty L. Serum adipokine levels predictive of liver injury in nonalcoholic fatty liver disease. Liver Int 2009;29:1431-8.
4. Centis E, Mar R, Di Domizi S Ciaella M,Marcesini G.ef estylhsnges in nonalcoholic fatty liver disease. Dig Dis 2010;28:267-73.
5. Oza N, Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Horie H, Ushirogawa M, Tsuzura T, Nakashita S, Takahashi H, Kawaguchi Y, Oda Y, Iwakiri R, Ozaki I, Eguchi T, Ono N, Fujimoto K. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modifi cation intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol 2009;44: 1203-18.
6. Bellentani S, Dalle Grave R, Suppini A, Marchesini G; Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008;47:746-54.
7. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M. Identifi cation of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443:709-12.
8. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, Randeva HS. Identifi cation of nesfatin-1 in human and murine adipose tissue: a novel depot-specifi c adipokine with increased levels in obesity. Endocrinology 2010;151: 3169-80.
9. Stengel A, Taché Y. Nesfatin-1-role as possible new potent regulator of food intake. Regul Pept 2010;163:18-23.
10. Nakata M, Manaka K, Yamamoto S, Mori M, Yada T. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca[2-[ infl ux through L-type channels in mouse islet-cells. Endocr J 2011;58:305-13.
11. Tanida M, Mori M. Nesfatin-1 stimulates renal sympathetic nerve activity in rats. Neuroreport 2011;22:309-12.
12. Öz savcí D, Es a hin M, S ̧ ener A, Ö z akpinar Ö B, Toklu HZ, Akak í n D, Ş ener G, Ye g en B Ç. The novel function of nesfatin-1 as an anti-infl ammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in rats. Neurosurgery 2011;68:1699-1708.
13. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic fi ndings in nonalcoholic fatty liver disease refl ects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;12:2708-15.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
15. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
16. Stengel A, Goebel M, Taché Y. Nesfatin-1: a novel inhibitory regulator of food intake and body weight. Obes Rev 2011; 12:261-71.
17. Stengel A, Tach é Y. Minireview: nesfatin-1-an emerging new player in the brain-gut, endocrine, and metabolic axis. Endocrinology. 201;152:4033-8.
18. Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Tach é Y, Sachs G, Lambrecht NW. Identifi cation and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009;150:232-8.
19. Shimizu H, Oh-I S, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, Okada S, Yamada M, Yada T, Mori M. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptinindependent mechanism. Endocrinology 2009;150:662-71.
20. Saldanha JF, Carrero JJ, Lobo JC, Stockler-Pinto MB, Leal VO, Calixto A, Geloneze B, Mafra D. The newly identifi ed anorexigenic adipokine nesfatin-1 in hemodialysis patients: are there associations with food intake, body composition and infl ammation? Regul Pept 2012;173:82-5.
21. Atsuchi K, Asakawa A, Ushikai M, Ataka K, Tsai M, Koyama K, Sato Y, Kato I, Fujimiya M, Inui A. Centrally administered nesfatin-1 inhibits feeding behaviour and gastroduodenal motility in mice. Neuroreport 2010;27;21:1008-11.
22. Tsuchiya T, Shimizu H, Yamada M, Osaki A, Oh-I S, Ariyama Y, Takahashi H, Okada S, Hashimoto K, Satoh T, Kojima M, Mori M. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol [Oxf] 2010;73:484-90.
23. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120:91-5.
24. Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S. Nesfatin-1 exerts a direct, glucosedependent insulinotropic action on mouse islet-and MIN6 cells. J Endocrinol 2011;208:9-16.
25. Foo KS, Brauner H, Ostenson CG, Broberger C. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 2010; 204:255-63.
26. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun 2010;391:1039-42.
27. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fl uctuation of nesfatin-1 level in normal humans. Regul Pept 2010;159:72-7.